Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | BACE1 | P56817 | 4/20 | 0.31 |
| ▸ | CTSD | P07339 | 3/20 | 0.31 |
| ▸ | NAAA | Q02083 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | RET | P07949 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20149635 | 0.92 | ATM (0.35) | ATMRET | |
| SCHEMBL20160379 | 0.85 | RET (0.38) | CNR2ATMRET | |
| SCHEMBL20148739 | 0.79 | CCR2 (0.35) | KMT2AEPHX1HPGDHSD11B1ALDH1A1 | |
| SCHEMBL20154522 | 0.74 | NAMPT (0.37) | RET | |
| SCHEMBL20682193 | 0.74 | JAK2 (0.34) | ATM | |
| SCHEMBL20160380 | 0.73 | RET (0.37) | CNR2RET | |
| SCHEMBL19001139 | 0.73 | CNR2 (0.49) | KMT2ACNR2HSD11B1ATMALDH1A1 | |
| SCHEMBL20149641 | 0.73 | ATM (0.42) | EPHX1ATMNAAA | |
| SCHEMBL14211219 | 0.72 | SMYD3 (0.36) | KMT2AEPHX1HPGDALDH1A1KDM4E | |
| SCHEMBL20070748 | 0.71 | EPHX1 (0.36) | EPHX1HSD11B1RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180134702-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180134702-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, ROR1, BRAF | KMT2A 1171/4885EPHX1 1665/4885CNR2 4312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.